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A B S T R A C T
The present guidelines on the management of unresectable non-metastatic non-small 
cell lung cancer (NSCLC) were formulated by the ELCWP in October 2005. They 
are designed to answer the following eight questions: 1) Is chest irradiation curative 
for NSCLC? 2) What are the contra-indications (anatomical or functional) to chest 
irradiation? 3) Does the addition of chemotherapy add an advantage to radiotherapy? 
4) Does the addition of radiotherapy add an advantage to chemotherapy? 5) Is ir-
radiation as effective as surgery for marginally resectable stage III? 6) How to best 
combine chemotherapy with radiotherapy: sequentially, concomitantly, as consolida-
tion, as induction, as radiosensitiser? 7) In case of too advanced locoregional disease, 
is there a role for consolidation (salvage) local treatment (surgery or radiotherapy) 
after induction chemotherapy? 8) In 2005, what are the technical characteristics of an 
adequate radiotherapy?
I N T R O D U C T I O N
This is the second of a series of five articles, reporting clinical practice guide-
lines for lung cancer, formulated by the European Lung Cancer Working Party 
(ELCWP). The articles will consecutively present the recommended treatment of 
early (resectable) stages of non-small cell lung cancer (NSCLC), locoregionally ad-
vanced NSCLC, metastatic NSCLC and small-cell lung cancer (SCLC) of limited 
and extensive stage. The rationale of the reasons and methodology used for those 
guidelines has been previously reported.
After an extensive discussion, a consensus was reached among members of the 
Group to formulate the guidelines of treatment of the unresectable non-metastatic 
stages of non-small lung cancer on the basis of eight predefined essential questions: 
1) Is chest irradiation curative for NSCLC? 2) What are the contra-indications (ana-
tomical or functional) to chest irradiation? 3) Does the addition of chemotherapy 
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add an advantage to radiotherapy? 4) Does the addition of 
radiotherapy add an advantage to chemotherapy? 5) Is irradia-
tion as effective as surgery for marginally resectable stage III? 
6) How to best combine chemotherapy with radiotherapy: 
sequentially, concomitantly, as consolidation, as induction, 
as radiosensitiser? 7) In case of too advanced locoregional 
disease, is there a role for consolidation (salvage) local 
treatment (surgery or radiotherapy) after induction chemo-
therapy? 8) In 2005, what are the technical characteristics 
of an adequate radiotherapy?
Those questions have been extensively discussed during 
a meeting organised in April 2005 in Brussels, in Belgium. 
The present consensus has been definitively approved by the 
Group in a final meeting in Bruges, in October 2005.
M E T H O D O L O G Y
Guidelines were established on the basis of the various 
data published in the literature: clinical trials, systematic 
reviews and meta-analyses, guidelines from medical societ-
ies or groups. Literature was identified and analysed by the 
evidence-based medicine group of the ELCWP. The quality 
of the published guidelines was assessed with the use of the 
AGREE instrument [1,2], allowing elimination of the worst 
ones and use of the best available ones for the establishment of 
our own guidelines. The following guidelines were selected: 
ASCO (American Society of Clinical Oncology) [3,4], BTS 
(British Thoracic Society) [5], Cancer Care Ontario Practice 
Guidelines [6], Royal College of Radiologists [7], American 
College of Chest Physicians (ACCP) [8] and FNCLCC (Fé-
dération Nationale des Centres de Lutte contre le Cancer) 
[9]. Selection was based on the previous assessment of the 
literature performed by the ACCP [10], and it was completed 
by the analysis using AGREE instrument of other guidelines 
that had not been taken into consideration. This approach 
allowed the addition of the FNCLCC and ACCP guidelines 
to the list.
Q U E S T I O N  1 :  I S  C H E S T  I R R A D I A T I O N  
C U R A T I V E  F O R  N S C L C ?
There is no published series of patients with unresectable 
locoregional NSCLC, treated with elective chest irradiation 
alone for which cure (more than 5-year disease-free survival) 
was documented. Evidence is indirect, mainly obtained from 
the control arms of randomised trials treated with irradiation 
alone or by extrapolation from series of inoperable patients 
with resectable NSCLC (stages I and II).
From the historical point of view, the first report of lung 
cancer treated with irradiation (low energy x-ray) was pre-
sented in 1915 by Cole from the Memorial Sloan Kettering 
Cancer Centre in New-York [11]. In 1942, Leddy at the Mayo 
Clinic in Rochester obtained a 4% 5-year survival in a series 
of 125 patients treated with irradiation (135-200 kV energy). 
Megavoltage irradiation was introduced in Canada in the 
late forties; in 1968, data from the Memorial Center of the 
period 1949 to 1960 were reviewed. A total of 1047 patients 
were treated with external irradiation and only two five-year 
survivors were observed .
In the meta-analysis of the NSCLC Collaborative Group 
[12], there was a total of 893 patients in the control arms of 
the trials testing irradiation with or without chemotherapy. 
Twenty- five patients were alive and followed up at 5 years but 
no information is available about their cancer status and the 
concomitant administration of other treatments. In a review 
of the literature about the curative role of radiotherapy, Dam-
strup and Poulsen identified many uncontrolled studies of 
patients with inoperable or unresectable tumours, showing a 
1-year survival rate ranging from 29 to 58% and a 5-year sur-
vival rate ranging 4-10% [13]. The data were not analysed by 
disease stage. A systematic review of radical radiotherapy for 
stage I/II NSCLC in patients not sufficiently fit for or declin-
ing surgery (medically inoperable) was performed by Rowell 
and Williams [14]. The authors identified two randomised 
(including the CHART trial [15] comparing two radiotherapy 
fractionation schedules) and 35 non- randomised trials, with 
more than two thousands patients. Overall 5-year survival 
ranged from 0 to 42%. These data were fully analysed in the 
guidelines of the FNCLCC [16] for the management of stage 
I and II NSCLC treated by radiotherapy alone.
Recommendation: the curative role of radiotherapy for 
unresectable stage III NSCLC is not fully demonstrated. 
Chest radiotherapy can probably cure less than 5% of those 
patients (level of evidence: uncontrolled series of patients). 
Chest irradiation should, in this situation, be combined with 
chemotherapy.
Q U E S T I O N  2 :  W H A T  A R E  T H E  C O N T R A -
I N D I C A T I O N S  ( A N A T O M I C A L  O R  
F U N C T I O N A L ) T O  C H E S T  I R R A D I A T I O N ?
ASCO, ACCP, FNCLCC and Ontario Cancer Care 
Practice provide evidence of some contra-indications to 
chest irradiation without mentioning data supporting their 
recommendations.
These contra-indications to radical radiotherapy include 
poor performance status (ECOG 2-3), weight loss >5-10%, 
inadequate pulmonary function and metastatic disease con-
fined to the thorax. In fact, some contra-indications are 
relative and others absolute. They are related to the general 
condition of the patient and the existence of comorbidities, 
the presence of pulmonary diseases compromising lung 
function and the extent of the tumour. A prerequisite for the 
administration of radical radiotherapy is the possibility to 
treat all the disease in a single irradiation field (including the 
primary tumour and lymph nodes involved). Presence of ex-
trathoracic or intrathoracic (including pleural involvement) 
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metastases is considered as an absolute contra-indication 
for curative irradiation. The size of the field is limited by 
the potential risk of lung toxicity, namely radiation pneu-
monitis. Various attempts have been made to define param-
eters derived from the dose-volume histogram to predict 
toxicity and define the ability to perform chest irradiation 
[17]. These parameters include the Vdose (percentage of 
CT-defined total lung volume receiving greater or equal 
than a threshold dose like 20, 25 or 30 Gy), the mean lung 
dose (MLP) or the normal time complication probability 
(NTCP). Despite the fact that they are related to the risk of 
developing radiation pneumonitis, their precision is insuf-
ficient to recommend their routine use.
Recommendation: Radical radiotherapy should be lim-
ited to non- metastatic tumours that can be treated within 
a single field, provided that there is adequate pulmonary 
function, lack of severe comorbidity and an acceptable 
general medical condition. All these parameters should 
be assessed by an experienced radiotherapist (level of 
evidence: experts opinion).
Q U E S T I O N  3 :  D O E S  T H E  A D D I T I O N  O F  
C H E M O T H E R A P Y  A D D  A N  A D VA N T A G E  
T O  R A D I O T H E R A P Y ?
Today, none of the guidelines of other scientific societies 
- ASCO, ACCP, FNCLCC, Ontario Cancer Care Practice 
– recommend radical chest irradiation alone. Instead they 
recommend combined administration of radiotherapy and 
platinum-based chemotherapy.
The evidence that chemotherapy adds an advantage to 
radical chest irradiation comes from multiple randomised 
trials (Tables I and II) and meta-analyses (Table III). Ran-
domised studies have compared radiotherapy alone with 
induction chemotherapy followed by irradiation or with 
radiosensitisation using cytotoxic drugs, mainly platinum 
derivatives. There are 12 “modern” trials having tested 
induction chemotherapy in this indication [18-32]. They 
are summarised in table I. Five have resulted in a statisti-
cally significant improvement in survival, confirmed by 
a specific meta-analysis [33]. Concerning chemotherapy 
induced radiosensitisation, 10 randomised trials are avail-
able as shown in table II [34-43]. Four indicate significantly 
improved survival, confirmed by two specific meta-analysis 
[33,44] (Table III).
Recommendation: Radical chest irradiation should 
not be administered as a single modality treatment in un-
resectable stage III NSCLC. It should be combined with 
platinum-based chemotherapy (level of evidence: multiple 
randomised trials and meta-analysis).
Q U E S T I O N  4 :  D O E S  T H E  A D D I T I O N  O F  
R A D I O T H E R A P Y  A D D  A N  A D VA N T A G E  T O  
C H E M O T H E R A P Y ?
Data are too limited to adequately address this question. 
Indeed, almost all randomised trials have been using chest 
irradiation alone, as a control arm. Only three trials, sum-
marised in table IV, have tested chemotherapy with or without 
thoracic radiotherapy [45-47]. The trial by Johnson et al [45] 
failed to show significant survival difference between treat-
ment with Vindesine alone, radiotherapy alone or combina-
tion of both. This study can be strongly criticised because 
both chemotherapy regimen and radiotherapy techniques used 
are obsolete. In the Kubota trial, the addition of radical chest 
irradiation after two courses of cisplatin-based chemotherapy 
resulted in significantly improved survival [46]. Comparing, 
in responders to three courses of MIP chemotherapy, three 
further courses of the same chemotherapy versus the addition 
of radical radiotherapy, the ELCWP group demonstrated 
significant benefit in terms of local control in favour of the 
combined modality approach [47]. A Scandinavian trial com-
paring chest irradiation (40 Gy) with chemotherapy (cisplatin 
+ etoposide) found no significant difference in survival but in 
this study the dose of irradiation administered was palliative, 
not with a curative intent [48].
Recommendation: Combined radiochemotherapy 
should be administered instead of chemotherapy alone in 
unresectable stage III NSCLC (level of evidence: two ran-
domised trials).
Q U E S T I O N  5 :  I S  I R R A D I A T I O N  A S  E F F E C T I V E  
A S  S U R G E R Y  F O R  M A R G I N A L LY  R E S E C T A B L E  
S T A G E  I I I ?
The preferred local treatment of Stage IIIA N2 disease is 
controversial. Surgery, radical radiotherapy or both have been 
proposed. The threshold between resectable and unresect-
able disease differs from surgeon to surgeon and there is a 
lack of published randomised trials on the topic, excepting a 
small feasibility study [49]. Very recently, at the ASCO 2005 
and at the World Conference of Lung Cancer, two large tri-
als were presented about the role of surgery in stage IIIA N2 
NSCLC.
In the North American INT 0139 trial, patients with 
initially resectable N2 disease were randomised between 
bimodality (chemotherapy with cisplatin and etoposide + 
radiotherapy) and trimodality (same + surgery) approaches. 
A total of 396 eligible patients were enrolled and there was no 
significant difference in survival between both arms. Surgery 
was nevertheless associated with improved progression-free 
survival. In addition, pneumonectomy, especially if complex, 
e.g. intrapericardial, appeared associated with a particularly 
high mortality (22% if standard and 29% if complex), while 
lobectomy had a very low mortality (1%). It is thus possible 
that surgery is beneficial, when a pneumonectomy is not 
required. In the EORTC trial 08941, enrolled patients had 
to have pathologically proven stage IIIA N2 NSCLC con-
sidered to be unresectable by the surgeon. Three courses of 
platinum-based chemotherapy was administered and in case 
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of response, patients were randomised between surgery (plus 
optional postoperative radiotherapy) or chest irradiation. On 
572 registered patients, 333 were randomised. No significant 
difference in survival was observed, with median survival time 
and 5 year survival rates of 16.4 months and 15.7% for surgery 
and 17.5 months and 14% for radiotherapy, respectively. Post-
operative mortality was 4%.
Recommendation: Treatment of marginally resectable 
stage IIIA N2 NSCLC should be multimodal and contains 
in any case chemotherapy. The choice between surgery and 
radical radiotherapy as local treatment should be based on the 
resectability of the disease after chemotherapy, on the pos-
sibility to include the disease in a single irradiation field and 
on the local capacities of the centre. Inclusion of those patients 
in clinical trials is highly recommended (level of evidence: 
unpublished randomised trials and expert opinion).
Q U E S T I O N  6 :  H O W  T O  B E S T  C O M B I N E  
C H E M O T H E R A P Y  A N D  R A D I O T H E R A P Y :  
S E Q U E N T I A L LY ,  C O N C O M I T A N T LY ,  A S  
C O N S O L I D A T I O N ,  A S  I N D U C T I O N ,  A S  
R A D I O S E N S I T I S E R ?
In their guidelines, the FNLCC recommends the sequen-
tial approach (induction chemotherapy followed by chest ir-
radiation) and the ACCP concurrent chemoradiotherapy in 
stage IIIB.
Evidence from randomised clinical trials is limited. 
TABLE I. Randomised trials comparing sequential chemotherapy and radiotherapy with irradiation alone (OR: objective 
response; MST: median survival time; yr: year; mo: month; pts: patients; CPA: cyclophosphamide; ADR: adriamycine; 
CDDP: cisplatin; RT: radiotherapy; NA: not available; S: significant; NS: not significant; VBL: vinblastine; MTX: metho-
trexate; VDS: vindesine; Ifo: ifosfamide; MMC: mitomycin C).
Reference treatment n pts
OR
(%)
MST
(mo)
2 yr
survival
p
Mattson,
1988 [18]
1. CPA-ADR-CDDP (2x) then RT (55Gy) 76 49 NA NA S
2. RT (55Gy) 78 44 NA NA
Dillman,
1990 [19;20]
1. CDDP-VBL (2x) then RT (60Gy) 78 46 13.8 26% S
2. RT (60Gy) 77 35 9.7 13%
Morton,
1991 [21]
1. MTX-ADR-CPA-CCNU (2x) then (60 Gy) 56 55 10. 21% NS
2. RT (60 Gy) 58 64 10. 16%
Le Chevalier,
1991 [22;23]
1. VDS-CPA-CDDP-CCNU (3x) then (65 Gy) 176 31 12 21% S
2. RT (65 Gy) 177 35 10 14%
Gregor,
1993 [24]
1. CDDP-VDS (2x) then RT (50 Gy) 39 62 12.1 NA NS
2. RT (50 Gy) 39 42 12.4 NA
Crino,
1993 [25]
1. CDDP-VP16 (3x) then RT (56 Gy) 29 53 12.1 28% NS
2. RT (56 Gy) 32 32 8.4 14%
Wolf,
1997 [26]
1. Ifo-VDS (2x) then RT (50 Gy) 37 57 13.7 24 % S
2. RT (50 Gy) 41 41 9 12%
Sause,
1995 [27,28]
1. CDDP-VBL (2x) then RT (60 Gy) 164 13.8 NA S
2. RT (60 Gy) 163 11.4 NA
3. bifractionated RT (69.6 Gy) 163 12.3 NA
Planting,
1996 [29]
1. CDDP-VDS (2x) then RT (55Gy) 37 41 12.0 NS
2. RT (55 Gy) 33 55 12.0
Brodin,
1996 [30]
1. CDDP-VP16 (2x) then RT (56 Gy) 163 26 11 21% NS
2. RT (56 Gy) 164 25 10.5 17%
Cullen,
1999 [31]
I. MMC-Ifo-CDDP 223 54 12 NS
II. RT 223 10
Mattson,
2003 [32]
I. Docetaxel (x3) then RT 134 28 14.8 NS
II. RT 140 12.6
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TABLE II. Randomised trials comparing irradiation with or without radiosensisation by chemotherapy (OR: objective 
response; MST: median survival time; yr: year; mo: month; wk: week; d: day; pts: patients; CDDP: cisplatin; RT: 
radiotherapy; CBDCA: carboplatin; NS: not significant; VBL: vinblastine).
reference Thoracic RT chemotherapy n MST
2 yr 
survival
p
Schaake-
Koning,
1992 [34]
30 Gy/10 x + 
25 Gy/10x (split)
I. - 108 13%
0.04II. CDDP (30 mg/m2/wk) 98 19%
III. CDDP (6 mg/m2/d) 102 26%
Trovo,
1992 [35]
45 Gy/15x I. - 88 10.3 mo
NS
II. CDDP (6 mg/m2/d) 85 10.0 mo
Blanke,
1993 [36]
60-65 Gy I. - 111 46 wk 13%
NS
II. CDDP (70 mg/m2/3 wk) 104 43 wk 18%
Jeremic,
1995 [37]
64,8 Gy
(bifractionated)
I. - 61 8 mo 25%
II. 1x/wk CBDCA (100 mg d1,2)
+ VP 16 (100 mg d1,2,3)
52 18 mo 35%
0,002
III. 1x/2wk CBDCA (20 mg d1,2)
+ VP16 (100 mg d1-5)
56 13 mo 27%
NS
Jeremic,
1996 [38]
69,6 Gy
(bifractionated)
I. - 65 14 mo 26%
0,02II. CBDCA (50 mg/d) + VP16 (50 
mg/d)
65 21 mo 43%
Bonner,
1998 [39]
60 Gy I. - 33
NS
II. CDDP(30x3) - VP16 (100x3) x 2 32
Ball,
1999 [43]
60 Gy 1x/d I. - 53
NS
II. CBDCA (70 d1-5) 54
60 Gy 2x/d III - 46
IV. CBDCA (70 d1-5) 51
Clamon,
1999 [40]
60 Gy d50 after 2 
induction courses by 
CDDP-VBL
I. – 120 13 mo
NSII. CBDCA 100 mg/m²/wk 130 13 mo
Groen,
2004 [41]
60 Gy (2 Gy/d 5x/wk) I. - 78 11.7 mo 28%
NS
II. CBDCA 20 mg/m²/d 82 11.8 mo 20%
Cakir,
2004 [42]
64 Gy (2 Gy/d 5x/wk) I. - 88 2% (3 yrs)
0.0002
II. CDDP (20 d1-5) 88 10% (3 yrs)
One phase II [50] and two phase III [51,52] randomised tri-
als (table V) have been published comparing concomitant 
versus sequential approach. In all three, statistically sig-
nificant improvement in survival was observed in favour 
of the concomitant treatment. Chemotherapy used consisted 
of cisplatin-based regimens. There are only two randomised 
trials comparing various platinum-based regimens in that 
indication (table VI). The first was a phase II design and the 
second a phase III [54], both failing to show better results 
with higher dosage of chemotherapy [53].
Recommendation: When radiochemotherapy has to be 
administered, the concomitant approach should be preferred 
to the sequential one. Chemotherapy should be cisplatin-
based (level of evidence: two randomised controlled phase 
III trials). There are no data in favour of radiochemotherapy 
as induction treatment rather than as consolidation treatment 
or in favour of radiosensitisation by platinum derivatives 
instead of administering full radiochemotherapy.
Q U E S T I O N  7 :  I N  C A S E  O F  T O O  A D VA N C E D  
L O C O R E G I O N A L  D I S E A S E ,  I S  T H E R E  A  R O L E  
F O R  C O N S O L I D A T I O N  ( S A LVA G E )  L O C A L  
T R E A T M E N T  ( S U R G E R Y  O R  R A D I O T H E R A P Y )  
A F T E R  I N D U C T I O N  C H E M O T H E R A P Y ?
There are no sufficient data on the topic, despite the fact 
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TABLE III. Meta-analyses of randomised trials performed in unresectable NSCLC (S: significant; NS: non significant; IMA: 
isolated meta-analysis; MAID: meta-analysis based on individual data of the trials; MASRL: meta-analysis performed 
in a systematic review of the literature)
Reference Methodology Outcome
Number of 
trials
Number of 
patients
Results
Chemotherapy added to radical radiotherapy
Collaborative Group, 1995 [12] MADI Overall survival 22 3033 S
Marino, 1995 [58] MASRL Survival at 1 and 2 years 14 1887 S (cisplatin)
Pritchard, 1996 [59] IMA Survival at 1, 2, 3 years 14 2589 S
Induction chemotherapy before radical radiotherapy
Sculier, 2001 [33] MASRL Overall survival 12 2274 S
Chemotherapy radiosensitising radical radiotherapy
Sculier, 2001 [33] MASRL Overall survival 08 1360 S
Rakovitch, 2004 [44] IMA Survival at 1, 2, 3 years 10 1802 S
TABLE IV. Randomised trials comparing chemotherapy with radiotherapy (OR: objective response; NC: no change; 
MST: median survival time; yr: year; mo: month; wk: week; d: day; pts: patients; CDDP: cisplatin; RT: radiotherapy; NA: 
not available; S: significant; NS: not significant; VDS: vindesine; Ifo: ifosfamide; MMC: mitomycin C).
reference treatment stage n % OR MST
3 yrs 
survival
(%)
p
Johnson,
1990 [45]
I. VDS Unresectable 106 10 10.1 mo 7
NSII. RT (60 Gy) 106 30 8.6 mo 5
III. RT + VDS 107 34 9.4 mo 7
Kubota,
1994 [46]
OR or NC after 2 courses CDDP-VDS 
(± MMC ± VP16)
III
S
I. - 32 50 447 d 3
II. RT (50-60 Gy) 31 52 461d 29
Sculier,
1999 [47]
RO after 3 courses of MMC-Ifo-CDDP III (2 yrs)
NSI. 3 further courses of chemotherapy 60 42 wk 18
II. RT (60 Gy) 55 54 wk 22
that administration of local treatment after good response 
sounds logical.
Recommendation: This question merits clinical inves-
tigations.
Q U E S T I O N  8 :  I N  2 0 0 5 ,  W H A T  A R E  T H E  
T E C H N I C A L  C H A R A C T E R I S T I C S  O F  A N  
A D E Q U A T E  R A D I O T H E R A P Y ?
Guidelines for lung cancer management do not provide 
clear recommendations for the technical aspects of radio-
therapy. For ASCO, the dosage should be no less than the 
biologic equivalent of 60 Gy, in 1.8 to 2.0 Gy fractions. For 
ACCP, there are no convincing data that hyperfractionated 
radiotherapy is superior to standard, once-daily treatment. 
For FNCLCC, a minimal dose of 60 Gy with a conventional 
fractionation and a weekly dose of 10 Gy should be admin-
istered, split course should not be used. Treatment should 
consist of photons given by a high energy linear accelerator. 
The technical aspects should conform to the guidelines of the 
International Commission on Radiation Units (ICRU reports 
29, 50 and 62) and to the recommendations of quality assur-
ance programmes (such as those of the French Society of On-
cological Radiotherapy). For Cancer Care Ontario Practice, 
chest irradiation should also be given at a dose of 60 Gy in 30 
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TABLE V. Randomised trials comparing concomitant with sequential chemoradiotherapy (OR: objective response; NC: 
no change; MST: median survival time; yr: year; mo: month; wk: week; d: day; pts: patients; CDDP: cisplatin; RT: radio-
therapy; VDS: vindesine; MMC: mitomycin C; VBL: vinblastine; VNR: vinorelbine)
Reference Treatment Stage N pts RO % MST 5 yr survival p
Furuse,
1999 [51]
I. Concomitant: CDDP-MMC-VDS x 2 
+ RT (56Gy d2)
IIIA/B 156 89 16.5 mo 15.8%
0.04
II. Sequential: CDDP-MMC-VDS x2 
then RT (56Gy)
158 66 13.3 mo 8.9%
Komaki,
2002 [50]
I. Concomitant: CDDP-VP16 + RT 
(69,6 Gy d1 bid)
81 71 15.5 mo 15.5%
II. Sequential: 2 x CDDP-VBL then RT 
(63 Gy d50) sensitised by CDDP
81 73 16.4 mo 13%
Zatloukal,
2004 [52]
I. Concomitant: CDDP-VNR (4 cycles) 
+ RT (60 Gy J4 cycle 2)
IIIA/B 52 80 16.6 mo
0.023
II. Sequential: CDDP-VNR x 4 then RT 
(60 Gy)
50 47 12.9 mo
TABLE VI. Randomised trials comparing various induction chemotherapy regimens (OR: objective response; MST: 
median survival time; yr: year; mo: month; pts: patients; CDDP: cisplatin; RT: radiotherapy; NS: not significant; gemci: 
gemcitabine; Ifo: ifosfamide; MMC: mitomycin C).
Reference modality regimen N pts OR MST 2 yr 
survival
p
Vokes,
2002 [55]
induction chemotherapy 
followed by 
consolidation 
radiochemotherapy
I. CDDP-gemci then RT-CDDP-
gemci
62 40% 18.3 m 37%
II. CDDP- paclitaxel then RT-
CDDP-paclitaxel
58 33% 14.8 m 29%
III. CDDP-vinorelbine then
 RT-CDDP-vinorelbine
55 45% 17.7 m 40%
Sculier,
2004 [56]
induction chemotherapy 
followed by 
consolidation 
radiotherapy (60 Gy)
I. MIP: MMC (6 mg/m²) + Ifo (3 
g/m²) + CDDP (50 mg/m²)
176 35% 12.5 m
NSII. SuperMIP: MMC (6 mg/m²) + 
Ifo (4.5 g/m²) + CDDP (60 mg/
m²) + carboplatin (200 mg/m²)
175 46% 11.2 m
fractions over a 6-week period. Hyperfractionated acceler-
ated radiotherapy should be performed only in the context of 
trials. Hypofractionation or split course should be used only 
for palliative purposes.
Evidence is mainly based on experts opinion. There 
are no published randomised trials having tested technical 
aspects (such as hyperfactionation or FDG-PET for volume 
delineation) in the context of a combined modality approach 
with chemotherapy for stage III NSCLC. The EORTC Ra-
diotherapy Group has published, in 2004, literature-based 
recommendations for treatment planning and administration 
of radical radiotherapy for lung cancer [55]. Those recom-
mendations concern patient’s positioning, planning CT scan 
(with the use of spiral CT scan), accounting for tumour mo-
bility, generating target volumes, treatment planning (has to 
be three-dimensional), treatment delivery and evaluation of 
response and toxicity. Target volume should use the ICRU 50 
definitions [56] for the gross tumour volume (GTV), the clini-
cal target volume (CTV) and planning target volume (PTV). 
There are insufficient data to support the use of elective modal 
irradiation for any patient. FDG-PET scans are superior to 
CT scan for staging mediastinal nodes and incorporation of 
the FDG-PET findings into CT-based planning scan results 
in changes to radiotherapy plans in a significant proportion 
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of patients [57].
Recommendation: Standard dosage with daily treatment 
and a minimal dose of at least 60 Gy over 6 weeks is recom-
mended for routine practice. EORTC Radiotherapy Group 
recommendations should be respected for treatment planning 
and administration of radiotherapy.
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